Association between genetic polymorphisms of long noncoding RNA H19 and cancer risk: a meta-analysis.
Journal
Journal of genetics
ISSN: 0973-7731
Titre abrégé: J Genet
Pays: India
ID NLM: 2985113R
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
entrez:
24
9
2019
pubmed:
24
9
2019
medline:
15
2
2020
Statut:
ppublish
Résumé
Long noncoding RNA (lncRNA) H19, a well-known oncogenic lncRNA, is overexpressed in various cancers. Several studies have investigated the association between polymorphisms in lncRNA H19 and the risk of various cancer types; however, the findings were inconsistent. In this study, we performed a meta-analysis to identify the precise association between H19 polymorphisms and cancer risk. Appropriate studies were retrieved from searching Web of Science, PubMed, Scopus, and Google scholar databases, updated 25 November 2018. The pooled odds ratios (ORs with 95% confidence intervals (CIs) were calculated to estimate the strength of the association between H19 polymorphisms and cancer risk. Our findings revealed that the H19-rs217727 C>T polymorphism is significantly associated with an increased risk of overall cancer in homozygous codominant (OR=1.28, 95% CI=1.04-1.57,
Substances chimiques
H19 long non-coding RNA
0
RNA, Long Noncoding
0
Types de publication
Journal Article
Meta-Analysis
Review
Langues
eng
Sous-ensembles de citation
IM
Références
N Engl J Med. 2000 Jul 13;343(2):78-85
pubmed: 10891514
PLoS One. 2007 Sep 05;2(9):e845
pubmed: 17786216
Eur Urol. 2008 Nov;54(5):1118-26
pubmed: 18262338
Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2007-11
pubmed: 18708391
Hum Mol Genet. 2009 Jun 15;18(12):2297-304
pubmed: 19304784
PLoS One. 2009 Jun 19;4(6):e5983
pubmed: 19543528
Bioessays. 2010 Jun;32(6):473-80
pubmed: 20486133
Carcinogenesis. 2010 Aug;31(8):1417-23
pubmed: 20554749
BMC Res Notes. 2012 Aug 07;5:414
pubmed: 22867275
Carcinogenesis. 2013 Mar;34(3):689-93
pubmed: 23188672
Br J Cancer. 2013 Jun 25;108(12):2419-25
pubmed: 23660942
BMC Cell Biol. 2013 May 27;14:26
pubmed: 23711233
Nat Rev Genet. 2014 Jan;15(1):7-21
pubmed: 24296535
Sci Rep. 2014 Aug 15;4:6088
pubmed: 25124853
Nat Genet. 2015 Mar;47(3):199-208
pubmed: 25599403
Neoplasma. 2015;62(3):412-8
pubmed: 25866221
Oncotarget. 2015 Jun 20;6(17):15311-20
pubmed: 25944697
Cell Physiol Biochem. 2015;36(4):1440-52
pubmed: 26160158
Tumour Biol. 2016 Jun;37(6):8349-58
pubmed: 26729200
Medicine (Baltimore). 2016 Feb;95(7):e2771
pubmed: 26886624
Oncotarget. 2016 May 3;7(18):25470-7
pubmed: 27027436
Mutagenesis. 2016 Sep;31(5):531-8
pubmed: 27091055
Oncotarget. 2016 Nov 22;7(47):76647-76655
pubmed: 27765929
Asian Pac J Cancer Prev. ;17(11):4985-4989
pubmed: 28032728
Mutat Res. 2017 Jan - Mar;771:1-14
pubmed: 28342449
Oncotarget. 2017 Jul 11;8(28):45143-45153
pubmed: 28404885
Methods Mol Biol. 2017;1617:1-25
pubmed: 28540673
J Biochem Mol Toxicol. 2017 Sep;31(9):null
pubmed: 28544374
World J Surg Oncol. 2017 Aug 17;15(1):155
pubmed: 28818070
Eur Rev Med Pharmacol Sci. 2017 Oct;21(17):3775-3780
pubmed: 28975992
Eur Rev Med Pharmacol Sci. 2017 Oct;21(17):3770-3774
pubmed: 28975993
Biosci Rep. 2018 Sep 5;38(5):
pubmed: 29511035
Minerva Urol Nefrol. 2019 Apr;71(2):161-167
pubmed: 29595036
Breast Cancer Res Treat. 2018 Aug;171(1):161-171
pubmed: 29737472
Oncotarget. 2018 Jan 2;9(35):23915-23922
pubmed: 29844862
BMC Med Genet. 2018 Aug 2;19(1):136
pubmed: 30071841
EXCLI J. 2018 Jun 28;17:608-619
pubmed: 30108465
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
BMC Cancer. 2018 Sep 15;18(1):893
pubmed: 30219045
Asian Pac J Cancer Prev. 2018 Oct 26;19(10):2709-2716
pubmed: 30360595
J Clin Lab Anal. 2019 Mar;33(3):e22826
pubmed: 30485527
J Gene Med. 2019 Jan;21(1):e3065
pubmed: 30549380
PLoS One. 2018 Dec 17;13(12):e0209342
pubmed: 30557328
EXCLI J. 2018 Sep 04;17:900-913
pubmed: 30564069
Genomics Inform. 2018 Dec;16(4):e18
pubmed: 30602079